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Abstract
A rare case of osteogenic sarcoma affecting the lower jaw is presented. Osteogenic sarcoma of
the jaw is a very rare tumor of the head and neck comprising less than 0.5% of all malignant
tumors of head and neck. Pertinent literature is reviewed to emphasize the various treatment
modalities and histopathological features for diagnosis of this rare tumour.
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Introduction
Osteogenic sarcoma (OS) is an uncommon tumour
accounting for 7,400 new cases and 4,200 new deaths
in the United States annually. Only 10% occur in head
& neck (1). Osteogenic sarcoma represent about 2.4%
of all childhood cancers and 56% of all malignant bone
tumors in children (2). As per literature, the osteogenic
sarcoma of jaw comprises of less than 0.5% of all
malignant tumors of head & neck (3). The involvement
of facial bones is rare, with maxilla and mandible
being the commonest bones affected along with
occasional involvement of frontal sinus and zygomatic
bones (4). The involvement of facial bones in
descending order of frequency, is maxilla, mandible,
skull and cervical spine (5). The incidence of OS of
jaw is higher in males than females with ratio of 3:2
and is more common in the younger age group i.e.
20-30 years (4). Several epidemiological risk factors,
related to development of OS include– a history of
ionising radiation exposure; fibrous dysplasia;
hereditary retinoblastoma; or prior exposure to thorium
oxide (1). The incidence of OS substantially increases
when the risk factors are combined.
We report a case of osteogenic sarcoma of the lower
jaw in a 20 year old male patient who failed to avail
proper medical/surgical treatment well in time leading
to huge size of the tumor giving gross disfigurement.
Case report
A 20 year old male patient with painless swelling of
the lower jaw including floor of mouth, more so on the
left side reported in the ENT OPD. Five years back, he
started with a swelling in the floor of the mouth on the
left side, which gradually increased in size. The swelling
was not associated with pain or any other
symptomatology of any system. There was no history of
trauma or exposure to radiations. Local examination
revealed an irregular swelling about 20cm×15cm in size,
more towards the left side. The swelling involved the
both rami of mandible and floor of mouth. At this time
it was not possible to pinpoint the site of origin. The
swelling was non-tender, with well defined margins,JK SCIENCE
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having visible pulsations. It was immobile, fixed, non-
compressive with raised local temperature and was firm
to hard in consistency. The skin over the swelling was
stretched and showing dilated visible veins over it. There
was a small ulcerated area on the floor of the mouth
towards left side. Loosening of teeth was also seen (Fig.
1). The patient was having moderate difficulty in
swallowing and his voice was altered. The ear, nose and
throat examination revealed no abnormality. Systemic
examination also failed to reveal any abnormality.
Routine investigations were all within normal limits. A
biopsy was taken and the histopathological examination
revealed an osteogenic sarcoma (Fig. 2).
Radicle resection of the tumor under general
anaesthesia followed by chemotherapy was planned for
this patient, but the patient refused surgery. For his
personal beliefs, he agreed only for radiotherapy. He was
given full course of palliative radiotherapy — 40 Gy/20
fractions with 12×12 field size directed to anterior lower
mandible. But the patient did not show any response.
Patient was motivated to undergo surgery, but he again
refused and did not turn up for follow-up.
Fig. 2. Photomicrograph showing diffuse sheets of malignant cells
directly laying down the osteoid-arrows (H&E 100X)
Discussion
The recent literature  from head & neck surgery
contains only infrequent case reports and small series
of osteosarcomas. The prognostic factors and optimal
management of OS of head and neck are, therefore,
poorly defined. Etiology of osteogenic sarcoma is
unknown. Radiation therapy (RT), paget's disease,
fibrous dysplasia and a history of trauma have all been
implicated in the pathogenesis of this tumor (4). OS
of jaw bones differ from OS of other regions and it
occurs a decade later. OS grows rapidly and invades
locally but have a limited tendency to metastise. The
most common presenting sign and symptoms of OS
include– an enlarging mass with or without pain or
paraesthesia; loosening of teeth; and firm, fixed
swelling (6). The present case also has the similar
features.
Radiology of OS shows areas of medullary
destruction with osteosclerosis or osteolysis. "Sunray"
spiculations radiating from the cortex into adjacent soft
tissues may be a feature. Over 80% of the patients
have micro-metastatic disease at the time of diagnosis,
most commonly in lungs (1). Distant metastasis occur
within 1 year in 80% of patients of OS of long bones,
but the rate of metastasis is high in case of jaws bones
(3). Histologically, OS consist of a malignant
undifferentiated stroma and neoplastic osteoid
formation along with increased mitotic rate of
proliferating stromal cells. The stromal component is
characterised by dense cellularity and pleomorphism
Fig. 1. Swelling arising from floor of mouth with loosening of teeth &
ulcer on floor of mouth.JK SCIENCE
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due to direct extension of the tumour into the brain
tissues (1). Preoperative radiotherapy prolongs the
survival as has been documented in OS of long bones
(3). In our patient the pre-operative radiotherapy was
given with the aim that pre-operative radiotherapy
enhances the local control with surgery and
chemotherapy by preventing or suppressing distant
metastases. After undergoing combined treatment with
surgery and chemotherapy, 50-60% of patients who
present with a localized OS are cured. But the
prognosis in patients with metastases at the time of
diagnosis is significantly worse, with few long-term
survivors (7). Furthermore, the skull lesions have
worse prognosis compared to others (1).
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(1). Similar findings have been observed in our
presentation. P53 mutations, increase in serum alkaline
phosphatase and immunohistochemical overexpression
of P185 have also been reported, with overexpression
of P185 correlated with poor outcome (4,7,8).
Overexpression of P185 (the product of HER-2/neu
oncogene, a– 185ICD protein) is seen in approximate
40% of primary OSs and even higher proportion (77%)
in metastatic tumors (2). The prognostic variables in
addition to stage of presentation of OS, which have
been seen to risk stratify OS patients include
clinicopathological parameters (e.g., p-glyco-protein,
expression and abrogation of P53, cyclin-D P16) (8).
The optimal management of patients with OS of
head and neck is unclear. Different authors have given
different treatment modalities e.g., radical surgery,
combined therapy employing surgery, R.T. and/or
chemotherapy. Improved local control and survival
have been seen with adjuvant RT with or without
chemotherapy. Five year survival rate have been
reported in 70-75% of patients receiving pre-operative
radiation followed by wide surgical excision and post-
operative chemotherapy (1). The OS of head & neck
have less risk of distant metastases but a higher rate
of local recurrence which may be due to difficulty in
achieving wide surgical margins in head & neck
surgeries due to anatomic and cosmetic reasons.
Radicle surgery alone results in local failure (1, 3).
Chemotherapy definitely reduces the risk of metastatic
recurrences (9). The modern management approach
involves- initial biopsy, then combination
chemotherapy followed by surgical excision aiming to
achieve clear surgical margins. Hemimandibulectomy
or radicle maxillectomy is undertaken in preference
to radiotherapy because OS is a relatively
radioresistent tumor (10). OS of jaws is more curable
than those that occur in long bones. The five-year
survival rate for OS of all site is 65-80% whereas that
for OS of jaws is 30% (3, 9). The death is usually